Literature DB >> 3425313

Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients.

S S Pedersen1, T Jensen, N Høiby, C Koch, E W Flensborg.   

Abstract

The annual mortality rate of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection at the Danish CF-centre ranged from 10 to 20% in the years 1970-1975. In this period the patients received antipseudomonal chemotherapy only during acute exacerbations of infection. From 1976 99 patients acquired chronic P. aeruginosa infection and were given regular and intensive antipseudomonal treatment 3-4 times per year. The patients were followed for 612 patient-years; 7 died and the 10-year survival rate after onset of P. aeruginosa infection was 90% +/- 4%. The annual mortality rate is now 1-2%. Although precipitating antibodies against P. aeruginosa increased significantly, pulmonary function did not deteriorate with duration of infection. Cross-infection between patients caused an increased incidence of chronic P. aeruginosa infection which was reduced by hygienic measures.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3425313     DOI: 10.1111/j.1651-2227.1987.tb17271.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  20 in total

1.  Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain.

Authors:  Michael D Parkins; Bryan A Glezerson; Christopher D Sibley; Kristen A Sibley; Jessica Duong; Swathi Purighalla; Christopher H Mody; Matthew L Workentine; Douglas G Storey; Michael G Surette; Harvey R Rabin
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

2.  Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  S S Pedersen; F Espersen; N Høiby; T Jensen
Journal:  J Clin Microbiol       Date:  1990-04       Impact factor: 5.948

3.  Nitric oxide production by polymorphonuclear leucocytes in infected cystic fibrosis sputum consumes oxygen.

Authors:  M Kolpen; T Bjarnsholt; C Moser; C R Hansen; L F Rickelt; M Kühl; C Hempel; T Pressler; N Høiby; P Ø Jensen
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

4.  Pseudomonas aeruginosa antibodies in blood spots from patients with cystic fibrosis.

Authors:  V Thanasekaraan; M S Wiseman; R J Rayner; E J Hiller; D J Shale
Journal:  Arch Dis Child       Date:  1989-11       Impact factor: 3.791

5.  Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark.

Authors:  H K Johansen; N Høiby
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

6.  Cross-reactive antigens shared by Pseudomonas aeruginosa, Helicobacter pylori, Campylobacter jejuni, and Haemophilus influenzae may cause false-positive titers of antibody to H. pylori.

Authors:  H K Johansen; A Nørgaard; L P Andersen; P Jensen; H Nielsen; N Høiby
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

Review 7.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

Review 8.  Infection control in cystic fibrosis.

Authors:  Lisa Saiman; Jane Siegel
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

9.  The age at onset of chronic Pseudomonas aeruginosa colonization in cystic fibrosis--prognostic significance.

Authors:  C Aebi; R Bracher; S Liechti-Gallati; H Tschäppeler; A Rüdeberg; R Kraemer
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

10.  Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis.

Authors:  S S Pedersen; N Høiby; F Espersen; C Koch
Journal:  Thorax       Date:  1992-01       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.